MAPT and supranuclear palsy, progressive, 1: The simulations (Fig. 4) suggest that neither of the two doses was able to reduce the uptake of synaptic cleft oligomeric tau in these PSP conditions, despite showing reasonable target engagement in the CSF and ISF and on monomeric tau in the synaptic cleft.